Exposure to Mycophenolate and Fatherhood

Area of Science:

• Immunology
• Transplantation Medicine
• Reproductive Health

Background:

• Mycophenolic acid (MPA) is a crucial immunosuppressant used post-organ transplantation.
• MPA is known to be teratogenic in women and may affect male fertility.
• Limited data exists on pregnancy outcomes fathered by men exposed to MPA.

Purpose of the Study:

• To investigate the outcomes of pregnancies fathered by renal transplant recipients exposed to MPA.
• To determine if paternal MPA exposure influences adverse birth outcomes.

Main Methods:

• A nationwide retrospective cohort study utilizing Norwegian registries.
• Included renal transplant men between 1995-2015.
• Compared pregnancy outcomes between MPA-exposed and unexposed fathers.

Main Results:

• No significant increase in malformation risks observed in children fathered by MPA-exposed men (3.9% vs. 2.6%).
• Birth weights were comparable between exposed and unexposed groups (3381g vs. 3429g).
• Average MPA dose was 1.42 ± 0.3 g/day with median trough concentration of 2.8 ± 1.6 mg/L.

Conclusions:

• Paternal exposure to MPA does not elevate the risk of adverse birth outcomes.
• Findings are reassuring for the continuation of MPA therapy in men.
• Supports paternal MPA use before, during, and after conception.